Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease
Conditions
End-stage Renal Disease
Trial Timeline
Aug 16, 2017 → Nov 12, 2019
NCT ID
NCT03099122About Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone is a approved stage product being developed by Sanofi for End-stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03099122. Target conditions include End-stage Renal Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03099122 | Approved | Completed |
Competing Products
20 competing products in End-stage Renal Disease